...
cgon-img

CG Oncology, Inc. Common stock, Common Stock

CGON

NSQ

$28.02

-$0.43

(-1.51%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.17B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.47M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$25.77 L
$50.23 H
$28.02

About CG Oncology, Inc. Common stock, Common Stock

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is based in Irvine, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCGONSectorS&P500
1-Week Return-2.94%-3.35%-2.97%
1-Month Return-14.57%-3.49%-0.66%
3-Month Return-28.36%-12.6%2.71%
6-Month Return-12.74%-6.91%7.21%
1-Year Return-24.62%1.19%23.04%

Financials

Dec '21Dec '22Dec '23
Total Revenue10.36M191.00K204.00K[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":1.84,"profit":true},{"date":"2023-12-31","value":1.97,"profit":true}]
Cost of Revenue10.00K15.00K45.75M[{"date":"2021-12-31","value":0.02,"profit":true},{"date":"2022-12-31","value":0.03,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit10.35M176.00K204.00K[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":1.7,"profit":true},{"date":"2023-12-31","value":1.97,"profit":true}]
Gross Margin99.90%92.15%100.00%[{"date":"2021-12-31","value":99.9,"profit":true},{"date":"2022-12-31","value":92.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses22.95M35.42M55.65M[{"date":"2021-12-31","value":41.24,"profit":true},{"date":"2022-12-31","value":63.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(12.61M)(35.25M)(55.45M)[{"date":"2021-12-31","value":-1260600000,"profit":false},{"date":"2022-12-31","value":-3524600000,"profit":false},{"date":"2023-12-31","value":-5544900000,"profit":false}]
Total Non-Operating Income/Expense(684.00K)(198.00K)13.75M[{"date":"2021-12-31","value":-4.98,"profit":false},{"date":"2022-12-31","value":-1.44,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(12.84M)(35.44M)(48.61M)[{"date":"2021-12-31","value":-1283900000,"profit":false},{"date":"2022-12-31","value":-3544300000,"profit":false},{"date":"2023-12-31","value":-4860700000,"profit":false}]
Income Taxes---[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes---[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(12.84M)(35.44M)(48.61M)[{"date":"2021-12-31","value":-1283900000,"profit":false},{"date":"2022-12-31","value":-3544300000,"profit":false},{"date":"2023-12-31","value":-4860700000,"profit":false}]
Income From Discontinued Operations---[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(12.84M)(35.44M)(48.61M)[{"date":"2021-12-31","value":-1283900000,"profit":false},{"date":"2022-12-31","value":-3544300000,"profit":false},{"date":"2023-12-31","value":-4860700000,"profit":false}]
EPS (Diluted)--(0.33)[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-33.09,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CGON
Cash Ratio 34.59
Current Ratio 35.32

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CGON
ROA (LTM) -15.70%
ROE (LTM) -19.76%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CGON
Debt Ratio Lower is generally better. Negative is bad. 0.03
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.97

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CGON
Trailing PE NM
Forward PE NM
P/S (TTM) 3166.51
P/B 4.04
Price/FCF NM
EV/R 2376.43
EV/Ebitda NM

FAQs

What is CG Oncology, Inc. Common stock share price today?

CG Oncology, Inc. Common stock (CGON) share price today is $28.02

Can Indians buy CG Oncology, Inc. Common stock shares?

Yes, Indians can buy shares of CG Oncology, Inc. Common stock (CGON) on Vested. To buy CG Oncology, Inc. Common stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CGON stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of CG Oncology, Inc. Common stock be purchased?

Yes, you can purchase fractional shares of CG Oncology, Inc. Common stock (CGON) via the Vested app. You can start investing in CG Oncology, Inc. Common stock (CGON) with a minimum investment of $1.

How to invest in CG Oncology, Inc. Common stock shares from India?

You can invest in shares of CG Oncology, Inc. Common stock (CGON) via Vested in three simple steps:

  • Click on Sign Up or Invest in CGON stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in CG Oncology, Inc. Common stock shares
What is CG Oncology, Inc. Common stock 52-week high and low stock price?

The 52-week high price of CG Oncology, Inc. Common stock (CGON) is $50.23. The 52-week low price of CG Oncology, Inc. Common stock (CGON) is $25.77.

What is CG Oncology, Inc. Common stock price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of CG Oncology, Inc. Common stock (CGON) is

What is CG Oncology, Inc. Common stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of CG Oncology, Inc. Common stock (CGON) is 4.04

What is CG Oncology, Inc. Common stock dividend yield?

The dividend yield of CG Oncology, Inc. Common stock (CGON) is 0.00%

What is the Market Cap of CG Oncology, Inc. Common stock?

The market capitalization of CG Oncology, Inc. Common stock (CGON) is $2.17B

What is CG Oncology, Inc. Common stock’s stock symbol?

The stock symbol (or ticker) of CG Oncology, Inc. Common stock is CGON

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top